Pfizer And Biontech Agreement

Under the agreement, Pfizer will pay $185 million U.S. to BioNTech in advances, including a cash payment of $72 million and a $113 million stake. BioNTech is entitled to future milestone payments of up to $563 million for a potential $748 million. Pfizer and BioNTech share development costs equally. Initially, Pfizer will finance 100% of the development costs and BioNTech will reimburse Pfizer for its 50% share of these costs during the commercialization of the vaccine. This press release contains «forward-looking statements» from BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may contain information about BioNTech`s efforts to combat COVID-19, but not limited to this: the opening date of clinical trials with BNT162 and the likely publication of data from these clinical trials; The date of authorization or authorization for the use of an emergency physician; The potential for additional supply agreements with other legal systems or the COVAX facility; The potential safety and effectiveness of BNT162; BioNTech and Pfizer`s cooperation in developing a potential COVID-19 vaccine; and BioNTech`s ability to provide quantities of BNT162 to support clinical development and, if approved, market demand, including our production estimates for 2020 and 2021. All forward-looking statements contained in this press release are based on BioNTech`s current expectations and beliefs in future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and negatively from the results presented or implied in such forward-looking statements. These risks and uncertainties include, among other things, competition for the creation of a vaccine against COVID-19; The ability to achieve comparable clinical outcomes in larger and more diverse clinical trials; The ability to effectively develop our production capacity; and other potential difficulties. An explanation of these risks and other uncertainties can be contained in BioNTech`s Management Report on Form 20-F, submitted to the SEC on March 31, 2020 and available on the SEC`s website at All information contained in this press release refers to the date of publication and BioNTech undertakes no commitment to update this information, unless required by law. NEW YORK – MAINZ, Germany-(BUSINESS WIRE)– Pfizer Inc.

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the U.S. Department of Health and Human Services and the Department of Defense to meet the U.S. administration`s goal of Operation Warp Speed to begin delivering 300 million doses of COVID-19 vaccines in 2021.